




RealRate

PHARMACEUTICAL 2015

Epirus Biopharmaceuticals Inc
Rank 131 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 292%, being 38% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	23,018
Cost of Goods Sold	0
Intangible Assets	25,468
Liabilities, Current	7,376
Liabilities, Non-Current	0
Other Assets	2,199
Other Compr. Net Income	0
Other Expenses	-43
Other Liabilities	0
Other Net Income	-2,632
Other Revenues	0
Property and Equipment	704
Research and Development	16,286
Selling, General and Administrative Expense	22,973

Output Variable	Value in 1000 USD
Assets	51,389
Liabilities	7,376
Expenses	39,216
Revenues	0
Stockholders Equity	44,013
Net Income	-41,848
Comprehensive Net Income	-41,848
BaseVar	50,306
ECR before LimitedLiability	184%
Economic Capital Ratio	292%